FRA:22UA • US09075V1026
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIONTECH SE-ADR (22UA.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-08-13 | SVB Leerink | Maintains | Market Perform |
| 2021-08-11 | Bryan Garnier | Upgrade | Neutral -> Buy |
| 2021-08-11 | HC Wainwright & Co. | Maintains | Neutral |
| 2021-06-16 | Redburn Partners | Downgrade | Neutral -> Sell |
| 2021-05-18 | Goldman Sachs | Initiate | Neutral |
| 2021-05-13 | Canaccord Genuity | Maintains | Buy |
| 2021-05-11 | Bryan Garnier | Downgrade | Buy -> Neutral |
| 2021-05-11 | SVB Leerink | Maintains | Market Perform |
| 2021-04-15 | SVB Leerink | Maintains | Market Perform |
| 2021-04-06 | SVB Leerink | Maintains | Market Perform |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 17.311B -8.78% | 3.819B -77.94% | 2.751B -27.96% | 2.821B 2.54% | 2.686B -4.79% | 2.756B 2.61% | 3.061B 11.07% | 3.09B 0.95% | 3.745B 21.20% | 5.191B 38.61% | 6.054B 16.62% | 6.59B 8.85% | |
| EBITDA YoY % growth | 12.423B -16.38% | 1.091B -91.21% | -860.8M -178.87% | -1.016B -18.06% | -899.096M 11.53% | -987.494M -9.83% | 389.85M 139.48% | 651.57M 67.13% | 1.403B 115.33% | 1.981B 41.20% | 2.538B 28.12% | N/A | |
| EBIT YoY % growth | 12.3B -16.79% | 908M -92.62% | -1.159B -227.62% | -1.281B -10.58% | -1.098B 14.35% | -1.346B -22.65% | -815.064M 39.46% | -697.079M 14.48% | -325.735M 53.27% | 1.025B 414.67% | 1.57B 53.17% | 1.866B 18.85% | |
| Operating Margin | 71.05% | 23.78% | -42.12% | -45.42% | -40.86% | -48.85% | -26.63% | -22.56% | -8.70% | 19.75% | 25.93% | 28.32% | |
| EPS YoY % growth | 36.93 -6.95% | 3.83 -89.63% | -2.78 -172.58% | -3.33 -19.75% | -3.53 -5.97% | -3.35 5.16% | -0.14 95.86% | -1.95 -1,308.54% | -1.61 17.75% | 2.54 258.16% | 4.65 83.20% | 6.27 34.75% |
All data in EUR
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.04 -103.35% | -1.99 -15.03% | -2.33 -45.35% | -0.30 -148.63% | 1.62 4,578.87% |
| Revenue Q2Q % growth | 810.4M -31.90% | 297.06M 62.51% | 239.35M -8.22% | 836.83M -44.91% | 1.001B 23.52% |
| EBITDA Q2Q % growth | -47.007M -109.78% | -420.527M 10.32% | -472.985M -25.63% | 25.285M -87.01% | N/A |
| EBIT Q2Q % growth | -136.868M -174.96% | -502.036M 1.89% | -588.458M -25.12% | -109.309M -367.13% | 204.35M 249.30% |
All data in EUR
28 analysts have analysed 22UA.DE and the average price target is 118.89 EUR. This implies a price increase of 50.31% is expected in the next year compared to the current price of 79.1.
BIONTECH SE-ADR (22UA.DE) will report earnings on 2026-03-10, before the market open.
The consensus EPS estimate for the next earnings of BIONTECH SE-ADR (22UA.DE) is -0.04 EUR and the consensus revenue estimate is 810.40M EUR.
The number of analysts covering BIONTECH SE-ADR (22UA.DE) is 28.